Article: Nabi Biopharmaceuticals Acquires Exclusive Rights to Novel Plasma Fractionation Technology from ProMetic Life Sciences.

-- Technology Expected to Give Company's Hyperimmune Product Candidates Key Competitive Advantages: Increased Yield and Better Product Margins --

BOCA RATON, Fla., Aug. 29 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals today announced that it has obtained the exclusive rights to use a novel hyperimmune immunoglobulin extraction technology from ProMetic Life Sciences Inc., a global biopharmaceutical company based in Montreal, Canada, in the manufacture of certain of Nabi Biopharmaceuticals' pipeline hyperimmune products. Access to this technology is expected to provide higher yields of Nabi Biopharmaceuticals' Civacir(R) [Hepatitis C Immune Globulin ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!